Details for New Drug Application (NDA): 020768
✉ Email this page to a colleague
NDA 020768 describes ZOMIG, which is a drug marketed by Amneal, IPR, and Astrazeneca, and is included in three NDAs. It is available from two suppliers. Additional details are available on the ZOMIG profile page.
The generic ingredient in ZOMIG is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
The generic ingredient in ZOMIG is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
Summary for 020768
| Tradename: | ZOMIG |
| Applicant: | Ipr |
| Ingredient: | zolmitriptan |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Nov 25, 1997 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Nov 25, 1997 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
